Q3 2025 BridgeBio Pharma Inc Earnings Call Transcript
Key Points
- BridgeBio Pharma Inc (BBIO) reported strong commercial execution with Attruby, achieving $108.1 million in net product sales for the quarter.
- The company announced positive Phase 3 results for BBP-418 in limb-girdle muscular dystrophy type 2i and encaleret in autosomal dominant hypocalcemia type 1, exceeding expectations.
- BridgeBio Pharma Inc (BBIO) maintains a robust financial position with $645.9 million in cash, cash equivalents, and marketable securities.
- The company is expanding its pipeline with promising assets like infigratinib for achondroplasia, expected to read out in early 2026.
- Attruby continues to gain market share, with a goal of achieving 30-35% market share by volume, supported by strong prescriber confidence and sustained demand.
- Operating expenses increased by $65.4 million compared to the previous year, primarily driven by higher SG&A expenses.
- There is a high annual dropout rate in the market, estimated at around 40%, which could impact long-term market share growth.
- The competitive landscape includes challenges from existing therapies like tafamidis and potential future generics.
- The company faces the challenge of expanding diagnosis rates for ATTR cardiomyopathy to reach the estimated 250,000 patients in the US.
- Market dynamics in Europe present pricing challenges, potentially affecting the ratio of sales between Europe and the US.
Good afternoon. I will be your conference operator today. (Operator Instructions)
Before we begin, I would like to remind everyone that today's call may contain forward-looking statements within the meaning of the federal securities laws, including, but not limited to, statements about BridgeBio's future operating and financial performance, business plans and prospects, and strategy. These statements are based on current expectations and assumptions that are subject to risks and uncertainties, which could cause actual results to differ materially from those expressed or implied in these forward-looking statements.
For a discussion of these risks and uncertainties, please refer to the disclosure in today's earnings release and BridgeBio's periodic reports and SEC filings. All statements made here are based on information available to BridgeBio as of today, and the company undertakes no obligation to update any forward-looking statements made during this call, except as required by law.
With that completed, BridgeBio, you may begin your conference.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
